(Total Views: 629)
Posted On: 07/13/2022 5:35:37 PM
Post# of 153908
Re: onestepahead #126368
Someone asked me about Novavax a few days ago. Hopefully they bought in.
Quote:
Where Novavax could be successful is because of lower cost. Which would lead to widespread use. There's also a niche marketplace in those who are reluctant to take mRNA vaccines. It could easily be $2+ billion in earnings. With $6 billion market cap it's on the low end. The current share price is on the low end of potential.
(2)
(0)
